Shaw and Partners Chief Investment Officer Martin Crabbe outlines a four-part investment strategy, focusing on growth, financial conditions, central bank policy and valuation. He notes that valuations remain high. He advises investors to adopt an active strategy, selecting individual growth-oriented stocks instead of relying on index funds.
Copyright 2024 – Finance News Network
27 Oct 2022 - icetana Limited (ASX:ICE) CEO and Managing Director Matt Macfarlane discusses the company's recent deal with Japanese group Macnica and the launch of a new product.
16 Aug 2023 - Yoav Amitai - CEO - Elsight's (ASX:ELS) Halo provides connectivity and delivers absolute connection confidence for drones and other unmanned systems.
22 Jun 2023 - Magnis Energy Technologies Limited (ASX:MNS) Managing Director (US) Hoshi Daruwalla discusses the UN/DOT 38.3 certification awarded to lithium-ion batteries produced at the IM3NY battery plant.
19 Dec 2023 - James Powell, General Manager - Investor Relations, Corporate Affairs and Sustainability for Rural Funds Management presents on the FY23 results of the Rural Funds Group (ASX:RFF).
16 Oct 2024 - Rita Gatt, National Lead Partner - Regulation, Security and Risk at Deloitte, discusses the revolutionary potential of quantum computing.
22 Jun 2023 - European Metals Holdings (ASX:EMH) Cinovec Project is strategically located in the heart of the growing European EV ecosystem in the northwest of the Czech Republic. Cinovec is a large historic lithium resource, with a clean pathway to underground development. EMH’s 51 per cent JV partner is the national utility CEZ a subsidiary of CEZ Group, which is owned 70 per cent by the Czech Government.
30 November 2022 - James Powell, the General Manager - Investor Relations, Corporate Affairs and Sustainability of the Rural Funds Group Limited (ASX:RFF) presents on the group's FY22 financial results.
28 Sep 2020 - Cyclopharm Limited (ASX:CYC) Managing Director and CEO James McBrayer provides an update on the company's US Phase 3 trial for Technegas, and USFDA approval process timeline, with commercial sales expected in the US for 2021.
